<DOC>
	<DOCNO>NCT02492503</DOCNO>
	<brief_summary>Experience substitute carboplatin cisplatin limit advanced recurrent cervix cancer counterpart GOG 158 , document therapeutic equivalency cisplatin/paclitaxel carboplatin/paclitaxel treatment ovarian cancer , perform cervix cancer population .</brief_summary>
	<brief_title>Effectiveness Chemotherapy Metastatic Recurrent Carcinoma Cervix</brief_title>
	<detailed_description>This trial prospective , randomized phase II pilot study . Consecutive patient metastatic , recurrent refractory carcinoma cervix enrol gynecology clinic IRCH , AIIMS take study take informed consent . Patients randomize two arm . Each arm shall contain 20 patient . The patient shall receive paclitaxel carboplatin q3wk first arm paclitaxel carboplatin q1 wk second arm .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically proven case squamous adenocarcinoma adenosquamous carcinoma 2.ECOG performance status 0,1 2 3.Adequate hematologic , renal liver function 4.Informed consent 5.Measurable disease CT scan USG abdomen MRI 1 . ECOG performance status 3 4 2 . Impaired blood count : patient absolute neutrophil count &lt; 1,500/μL , platelet count &lt; 100,000/μL , ineligible . 3 . Impaired renal /liver function indicate : Serum bilirubin &gt; 1.5× normal , AST level 3× normal , Alkaline phosphatase level 3× institutional normal , Serum creatinine level 1.2 mg/dL . Patients serum creatinine level 1.2 mg/dL less 1.5 mg/dL eligible creatinine clearance 70 ml/min eligible creatinine clearance determination 50 mL/min . 4 . H/o prior chemotherapy metastatic disease , 5 . H/O concurrent past malignancy carcinoma cervix , 6 . CNS metastasis , 7 . Bilateral hydronephrosis could alleviate ureteral stent percutaneous nephrostomy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>recurrent metastatic carcinoma cervix chemotherapy</keyword>
</DOC>